CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) reports financial results for the three and nine months ended September 30, 2022 and provides a business update. On September 9, 2022, Ra Medical entered into an Agreement and Plan of Merger (the “Definitive Merger Agreement”) with privately held Catheter Precision … [Read more…]
Conference Call to be held Tuesday, November 15, 2022 at 5:00 pm (EST) DUBLIN, Ohio–(BUSINESS WIRE)–The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company’s Vice Chair of the Board of Directors, John K. Scott, Jr. (Instead of: Received an additional $1.5 … [Read more…]
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening … [Read more…]
LITTLE ELM, Texas–(BUSINESS WIRE)–Retractable Technologies, Inc. (NYSE American: RVP) reports that its operating income was $7.0 million for the first nine months of 2022 and that it had an operating loss of $691 thousand for the third quarter of 2022, as compared to an operating income for the same periods last year of $44.1 million … [Read more…]
EMERYVILLE, Calif.–(BUSINESS WIRE)–Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset NPM-119 for the treatment of patients with type 2 diabetes, today announced financial results for the third quarter ending September 30, 2022 and provides business updates. Recent Business Highlights The merger of Second … [Read more…]
EsoGuard test volume increased 28% sequentially and 436% annually Conference call and webcast to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–#CheckYourFoodTube—Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for … [Read more…]
MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it is postponing its earnings conference call. The Company will issue a press release announcing the new date and time for the postponed … [Read more…]
-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to … [Read more…]
CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress. Corporate Update As previously reported, on September 26, 2022, the Company … [Read more…]
-FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications– -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused … [Read more…]
